Incyte Corporation - Common Stock (NQ:INCY)

113.31 UNCHANGED

Delayed Quote Updated: 4:00 PM EDT, Oct 26, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Incyte Corporation - Common Stock

< Previous 1 2 3 4 5 6 7 8 9

...

29 30 Next >

Incyte Japan Announces Approval of Minjuvi® (tafasitamab) in Combination with Rituximab and Lenalidomide for the Treatment of Relapsed or Refractory Follicular Lymphoma

December 22, 2025

From Incyte

Via Business Wire

Incyte Japan Announces Approval of Zynyz® (retifanlimab) for the First-Line Treatment of Advanced Anal Cancer

December 22, 2025

From Incyte

Via Business Wire

Incyte to Present at Upcoming Investor Conference

December 18, 2025

From Incyte

Via Business Wire

Incyte Announces European Commission Approval of Minjuvi® (tafasitamab) for the Treatment of Relapsed or Refractory Follicular Lymphoma

December 17, 2025

From Incyte

Via Business Wire

Incyte Announces Change to its Board of Directors

December 12, 2025

From Incyte

Via Business Wire

Monday's session: top gainers and losers in the S&P500 index ↗

December 08, 2025

Curious about the S&P500 stocks that are in motion on Monday? Join us as we explore the top movers within the S&P500 index during today's session.

Via Chartmill

Explore the top gainers and losers within the S&P500 index in today's session. ↗

December 08, 2025

Stay informed about the performance of the S&P500 index in the middle of the day on Monday. Uncover the top gainers and losers in today's session for valuable insights.

Via Chartmill

These S&P500 stocks are gapping in today's session ↗

December 08, 2025

Stay tuned for the market movements in the S&P500 index on Monday. Check out the gap up and gap down stocks in the S&P500 index during today's session.

Via Chartmill

Incyte’s First-in-Class mutCALR-Targeted Monoclonal Antibody, INCA033989, Granted Breakthrough Therapy Designation by U.S. FDA

December 07, 2025

From Incyte

Via Business Wire

Incyte Announces New Positive Data for INCA033989, its First-In-Class mutCALR-Targeted Monoclonal Antibody, in Patients with Myelofibrosis Presented at ASH 2025

December 07, 2025

From Incyte

Via Business Wire

Incyte Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

December 03, 2025

From Incyte Corporation

Via Business Wire

2 S&P 500 Stocks Worth Investigating and 1 We Brush Off

December 03, 2025

The S&P 500 (^GSPC) is often seen as a benchmark for strong businesses, but that doesn’t mean every stock is worth owning. Some companies face significant challenges, whether it’s stagnating growth,...

Via StockStory

Topics Stocks

Incyte and Winnie Harlow Join Forces to Share Her Personal Vitiligo Story and Spark Conversation and Understanding

December 02, 2025

From Incyte

Via Business Wire

Gapping S&P500 stocks in Monday's session ↗

December 01, 2025

Curious about the S&P500 stocks that are gapping on Monday? Explore the gap up and gap down stocks in the S&P500 index during today's session.

Via Chartmill

Incyte Appoints Richard Hoffman as Executive Vice President and General Counsel

December 01, 2025

From Incyte

Via Business Wire

Top S&P500 movers in Friday's session ↗

November 28, 2025

Let's delve into the developments on the US markets one hour before the close of the markets on Friday. Below, you'll find the top gainers and losers within the S&P500 index during today's session.

Via Chartmill

Gapping S&P500 stocks in Friday's session ↗

November 28, 2025

Curious about the S&P500 stocks that are gapping on Friday? Explore the gap up and gap down stocks in the S&P500 index during today's session.

Via Chartmill

INCYTE CORP (NASDAQ:INCY) Fits Minervini Trend Template with Strong Growth Momentum ↗

November 26, 2025

INCYTE stock shows strong technical uptrends per Minervini's Trend Template, backed by accelerating earnings and revenue growth for high momentum.

Via Chartmill

2 Growth Stocks Set to Flourishand 1 Facing Challenges

November 25, 2025

Growth is oxygen. But when it evaporates, the consequences can be severe - ask anyone who bought Cisco in the Dot-Com Bubble or newer investors who lived through the 2020 to 2022 COVID cycle.

Via StockStory

Integra LifeSciences, Evolent Health, Incyte, iRhythm, and Clover Health Stocks Trade Up, What You Need To Know

November 24, 2025

A number of stocks jumped in the afternoon session after a report revealed that the White House plans to pitch a two-year extension of Obamacare subsidies.

Via StockStory

Topics Economy

Q3 Earnings Highs And Lows: Exact Sciences (NASDAQ:EXAS) Vs The Rest Of The Immuno-Oncology Stocks

November 23, 2025

As the Q3 earnings season wraps, let’s dig into this quarter’s best and worst performers in the immuno-oncology industry, including Exact Sciences (NASDAQ:EXAS) and its peers.

Via StockStory

Topics Artificial Intelligence

November 20, 2025

When Wall Street turns bearish on a stock, it’s worth paying attention. These calls stand out because analysts rarely issue grim ratings on companies for fear their firms will lose out in other...

Via StockStory

Spotting Winners: Natera (NASDAQ:NTRA) And Immuno-Oncology Stocks In Q3

November 19, 2025

The end of an earnings season can be a great time to discover new stocks and assess how companies are handling the current business environment. Let’s take a look at how Natera (NASDAQ:NTRA) and the...

Via StockStory

Topics Artificial Intelligence

Incyte to Present at Upcoming Investor Conferences

November 19, 2025

From Incyte

Via Business Wire

Top S&P500 movers in Tuesday's pre-market session ↗

November 18, 2025

Discover the top S&P500 movers in Tuesday's pre-market session and stay informed about market dynamics.

Via Chartmill

INCYTE CORP (NASDAQ:INCY) Presents a Compelling Case for Value Investors ↗

November 18, 2025

INCYTE CORP (INCY) is a strong value investing candidate with a low P/E ratio, a healthy balance sheet, and solid profitability, suggesting it's an undervalued stock.

Via Chartmill

This Fund Sold $30 Million in PTC Therapeutics Shares Amid a 93% Rally: Here’s Why ↗

November 18, 2025

A healthcare hedge fund just trimmed its biggest holding—right as the company posts a clinical and financial breakout year.

Via The Motley Fool

Topics Regulatory Compliance

Why This Fund Trimmed a $161 Million Travere Position After a 100% Rally ↗

November 18, 2025

A healthcare hedge fund just locked in gains on one of its biggest winners—here’s what that move really signals.

Via The Motley Fool

Fear Of An AI Bubble? This Sector Is Quietly Surging While Tech Sinks ↗

November 14, 2025

While AI stocks slide, healthcare is soaring. XLV leads November gains, outperforming tech as investors rotate.

Via Benzinga

Topics Artificial Intelligence

1 Mid-Cap Stock to Consider Right Now and 2 We Turn Down

November 13, 2025

Many investors pay attention to mid-cap stocks because they have established business models and expansive market opportunities. However, their paths to becoming $100 billion corporations are ripe with...

Via StockStory

< Previous 1 2 3 4 5 6 7 8 9

...

29 30 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io. Quotes delayed at least 20 minutes. Market data may be delayed. Research information, not personalized advice.